Although PD-L1 is a promising target for immunotherapy in osteosarcoma patients [7], PD-L1-targeted immunotherapy is not effective despite the high PD-L1 positive rate in the tumor tissues [4, 8]. The gene discussed is CD274; the disease is neoplasm.